Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Quince Therapeutics, Inc. - Common Stock
(NQ:
QNCX
)
1.630
-0.050 (-2.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Quince Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
July 16, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
July 10, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
June 25, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 18, 2025
Via
Benzinga
Top movers in Wednesday's after hours session
June 18, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
June 18, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
June 12, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
June 03, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
May 13, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
May 05, 2025
Via
Benzinga
Quince Therapeutics to Present at Citizens Life Sciences Conference
April 30, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
April 03, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
March 24, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
February 07, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
February 04, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
January 28, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
January 27, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
January 23, 2025
From
Quince Therapeutics, Inc.
Via
Business Wire
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
December 18, 2024
Via
Benzinga
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
November 12, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
November 11, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
November 07, 2024
Via
Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 25, 2024
Via
Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
October 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 24, 2024
Via
Benzinga
Quince Therapeutics to Participate at Upcoming Investor Conferences
October 14, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Quince Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.